Globe Newswire

EVANSVILLE, Ind., June 01, 2024 (GLOBE NEWSWIRE) -- In recognition of National Homeownership Month, First Federal Savings Bank and the Independent Community Bankers of America (ICBA) are encouraging consumers to consult their local community banker about how to make the homebuying process simple, efficient and more affordable.

“Owning a home is a major purchase and an important component in building financial independence,” said Elisa Snyder FVP, Retail Lending... (continue reading...)

• In 17 EGFR wild-type (EGFRwt) non-small cell lung cancer (NSCLC) patients who failed chemotherapy and PD-1/PD-L1, AFM24 plus atezolizumab achieved 4 objective responses; 3 of 4 responses were ongoing for more than 7 months and progression free survival (PFS) was 5.9 months
• Objective responses were also seen in 4 of 13 response-evaluable EGFR mutant (EGFRmut) NSCLC patients confirming the activity of AFM24 and atezolizumab in heavily pretreated NSCLC patients
• In both NSCLC... (continue reading...)

TORONTO, June 01, 2024 (GLOBE NEWSWIRE) -- The Ontario Federation of Labour (OFL) was pleased to support several events across Ontario today, as injured workers and their allies marked Injured Workers’ Day in the province.

“For decades, injured workers have been leading the fight for justice for workers injured on the job,” said Laura Walton, OFL President. “We echo their call for a comprehensive compensation system that covers all workers and real income... (continue reading...)

CALGARY, Alberta, June 01, 2024 (GLOBE NEWSWIRE) -- Prospera Energy Inc. ("Prospera" or the "Corporation") (PEI: TSX-V; OF6A: FRA)

2023 was a transformational year for Prospera transforming to horizontal well technology in the Saskatchewan heavy-oil fields. Also, to initiate medium/light-oil development to diversify from predominately a heavy oil producer. The company successfully drilled, completed, and tied in 9 horizontal wells in its Saskatchewan heavy-oil fields... (continue reading...)

• An additional 19 patients have been enrolled since January 2024 bringing the total to 37 of whom 25 were evaluable for efficacy
• SYS6002 (CRB-701) demonstrated 44% ORR and 78% DCR in mUC and 43% ORR and 86% DCR in cervical cancer to date at doses ≥ 1.2mg/Kg
• No dose limiting toxicities (DLTs) have been observed to date in doses up to and including 4.5 mg/Kg (cohort 7)
• Three cases of skin rash (including one grade 3) and one case of grade 1 neuropathy seen to date; all... (continue reading...)